tirilazad 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4063 | 110101-66-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
a lazaroid; potent inhibitor of iron-dependent lipid peroxidation; has shown excellent activity in in vivo models of experimental central nervous system trauma & ischemia; structure given in first source; tradename Freedox
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.42 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 9.80 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 7 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.01 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 49.30 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N07XX01 | NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS OTHER NERVOUS SYSTEM DRUGS Other nervous system drugs |
| MeSH PA | D000975 | Antioxidants |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D018696 | Neuroprotective Agents |
| MeSH PA | D020011 | Protective Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.26 | Basic |
| pKa2 | 7.62 | Basic |
| pKa3 | 2.97 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Beta-2 adrenergic receptor | GPCR | Ki | 4.81 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | Ki | 6.24 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 4.93 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 2C | GPCR | Ki | 6.43 | DRUG MATRIX | |||||
| Histamine H2 receptor | GPCR | Ki | 4.86 | DRUG MATRIX | |||||
| Alpha-2C adrenergic receptor | GPCR | Ki | 5.94 | DRUG MATRIX | |||||
| Epidermal growth factor receptor | Kinase | IC50 | 4.69 | DRUG MATRIX | |||||
| Tyrosine-protein kinase Lck | Kinase | IC50 | 4.80 | DRUG MATRIX | |||||
| Tyrosine-protein kinase Fyn | Kinase | IC50 | 5.95 | DRUG MATRIX | |||||
| Mitogen-activated protein kinase 3 | Kinase | IC50 | 4.79 | DRUG MATRIX | |||||
| Mitogen-activated protein kinase 14 | Kinase | IC50 | 5.13 | DRUG MATRIX |
External reference:
| ID | Source |
|---|---|
| D01930 | KEGG_DRUG |
| 111793-42-1 | SECONDARY_CAS_RN |
| 4025275 | VANDF |
| CHEBI:32233 | CHEBI |
| CHEMBL1630578 | ChEMBL_ID |
| CHEMBL1908849 | ChEMBL_ID |
| CHEMBL3989513 | ChEMBL_ID |
| CHEMBL1908330 | ChEMBL_ID |
| C053355 | MESH_SUPPLEMENTAL_RECORD_UI |
| 6616 | INN_ID |
| DB13050 | DRUGBANK_ID |
| YD064E883I | UNII |
| 59827 | RXNORM |
| 007860 | NDDF |
| 007861 | NDDF |
| C0245179 | UMLSCUI |
| 104903 | PUBCHEM_CID |
Pharmaceutical products:
None